#71 – Katherine Eban: Widespread fraud in the generic drug industry

Investigative journalist, Fortune magazine contributor, Andrew Carnegie fellow, and author of the book 'Bottle of Lies,' which exposes fraud in the generic drug industry.

A figure in the Bush White House at the time PEPFAR was debated, who initially referred to Indian generics as 'counterfeits' due to quality concerns, but later became FDA Commissioner.

Dinesh Thakur's boss at Ranbaxy, a blue-chip professional hired from GlaxoSmithKline, who tasked Thakur with investigating potential fraud and was eventually forced to resign after presenting evidence to the board.

Host of the NPR program 'The People's Pharmacy,' who in 2008 alerted Katherine Eban to widespread listener complaints about generic drugs, prompting her investigation.

The FDA reviewer who famously refused to approve thalidomide in the US, becoming a hero for preventing widespread birth defects linked to the drug.

A friend of the host, Peter Attia, who recommended Katherine Eban's book and inspired the podcast interview after expressing outrage over its contents.

A young engineer recruited by Ranbaxy from Bristol-Myers Squibb. He uncovered systemic data fraud at the company, leading him to become a whistleblower against Ranbaxy.

The CEO of Ranbaxy, who was part of the scion family that founded the company and was involved in orchestrating the fraud, eventually selling his shares for billions and later being ordered to pay restitution.

FDA Commissioner at the time Dinesh Thakur, under a pseudonym, sent him emails pleading for action against Ranbaxy.

A young, analytical chemist and FDA investigator who volunteered for the chronically understaffed India office in 2012, pioneering new inspection methods focusing on metadata in quality control labs, and uncovering data fraud in four-fifths of the 86 drug plants he inspected in India and China.

An investigative journalist whose work on cartel-like pricing in the antibiotic market and subsequent advocacy led to the creation of the Hatch-Waxman Act, establishing a pathway for generic drugs.

Katherine Eban's book investigating the widespread deceit and fraudulence in the generic drug manufacturing industry.

An NPR radio program run by Joe Graedon, which received numerous complaints about generic drug side effects, triggering Katherine Eban's investigation.

A branded erectile dysfunction drug (sildenafil) used as an example of a drug whose generic version would attract manufacturers after patent expiration.

A branded drug for severe acne with significant dangerous side effects, for which Ranbaxy launched a defective generic version (Sotret) knowing it was faulty and not dissolving properly.

A branded lipid-lowering drug (atorvastatin) frequently mentioned as an example of a high-value drug for which generic versions sought market approval.

The generic version of Accutane produced by Ranbaxy, which was known by the company to be defective, not dissolving properly, and requiring a 'do not share with FDA' cover sheet on its internal documents.

An immunosuppressant drug used for organ transplant patients, whose generic version led some heart transplant patients to suffer organ rejection at the Cleveland Clinic due to instability.

A drug widely dispensed in Europe in the early 1960s to pregnant women for morning sickness, but refused approval by the fledgling FDA in the US due to safety concerns, as it was later associated with severe birth defects.

A drug commonly prescribed for diabetes, whose generic extended-release versions are often reported by patients as being less effective or causing more gastrointestinal side effects than the branded Glucophage XR.

A blood pressure medication, along with losartan and irbesartan, that was found to have active ingredients contaminated with carcinogens from Chinese and Indian manufacturing plants, leading to widespread recalls.

A branded lipid-lowering drug whose generic equivalent (rosuvastatin) was ineffective for some of Peter Attia's patients, with zero change in LDL cholesterol, suggesting drug malfunction or fraudulent production.

The branded extended-release version of Metformin, which patients often find more effective and tolerable than generic extended-release Metformin.

A US government initiative launched by George W. Bush in 2003 to combat the AIDS crisis in Africa by purchasing low-cost generic drugs from India, which inadvertently boosted the legitimacy of Indian drug manufacturers.

A landmark US law that created a streamlined pathway for generic drugs at the FDA, waiving the need for generics to repeat full clinical trials but requiring bioequivalence, and introducing a 'first-to-file' exclusivity incentive.

A Western pharmaceutical company known for its heavily regulated environment, where Raj Kumar worked before joining Ranbaxy, contrasting with Ranbaxy's lawless culture.

A small, mail-order pharmacy based in New Haven, Connecticut, that differentiates itself by testing every drug it dispenses, and identified a fourth carcinogen in recalled blood pressure medications that the FDA missed.

India's largest generic drug company, which became the focus of Katherine Eban's investigation due to widespread data fabrication and fraudulent manufacturing practices across its global drug filings.

A highly regulated Western pharmaceutical company where Dinesh Thakur worked before Ranbaxy, highlighting the contrast in corporate culture and regulatory compliance.

A Chinese manufacturing plant that an FDA inspector recommended sanctioning for not investigating impurity spikes, but whose findings were downgraded by FDA officials, leading to a worldwide recall one year later due to carcinogen contamination.

An Indian drug company for which an employee was caught smuggling a garbage bag of incriminating documents during a Peter Baker inspection, revealing manufacturing of sterile injectable cardiac drugs on corroded equipment.

The US regulatory body responsible for ensuring the safety and efficacy of food and drugs, whose history, regulatory processes, and challenges with generic drug oversight are central to the discussion.

A Hindi word describing a spirit of creativity to overcome obstacles, but also having a dark connotation meaning to obtain a desired goal by any means necessary, often involving disregard for rules and regulations, which was prevalent in Ranbaxy's corporate culture.

Substances found contaminating blood pressure medications like valsartan, losartan, and irbesartan, originating from Chinese and Indian manufacturing plants, highlighting the severe safety risks of fraudulent drug production.

A 24-slide PowerPoint presentation compiled by Dinesh Thakur and Raj Kumar, detailing the widespread data fabrication at Ranbaxy across 200 drug products in 40 countries, which the company's board attempted to bury.

A poisonous substance that tainted a cough syrup in the 1930s, leading to child deaths and galvanizing public sentiment for the creation of the FDA.

A city in India, outside of New Delhi, where Dinesh Thakur moved his family to work for Ranbaxy, and where he encountered the company's chaotic and fraudulent operations.